Summary
IDEXX Laboratories, Inc. (IDXX) filed its 2002 Form 10-K on March 20, 2003, detailing a year of steady revenue growth, primarily driven by its Companion Animal Group (CAG), which accounted for 79% of total sales. The company reported total revenue of $412.7 million for the year ended December 31, 2002, a 7% increase from the prior year. This growth was fueled by strong performance in laboratory services, instrument consumables, and rapid assay products within the veterinary diagnostics sector. The company continues to invest in research and development, with expenses totaling $29.3 million in 2002, focusing on new diagnostic platforms, animal drugs, and improved testing products. IDEXX also highlighted the successful adoption of SFAS No. 142, which eliminated goodwill amortization, positively impacting its effective tax rate. While the company faces competition and regulatory scrutiny, its financial position appears robust, with significant cash and investments and a commitment to reinvesting earnings for future growth, as no dividends are currently paid.
Key Highlights
- 1Total revenue grew by 7% to $412.7 million for the year ended December 31, 2002.
- 2The Companion Animal Group (CAG) remains the dominant segment, representing 79% of total sales, with notable growth in laboratory services, instrument consumables, and rapid assay products.
- 3The Food and Environmental Group (FEG) also demonstrated growth, increasing revenue by 10%, driven by poultry, livestock, and water testing products.
- 4Research and development expenses were $29.3 million, reflecting ongoing investment in new product development.
- 5The company adopted SFAS No. 142, ceasing goodwill amortization, which positively impacted its effective tax rate.
- 6IDEXX has a strong liquidity position with $162.8 million in cash and investments and $213.4 million in working capital as of December 31, 2002.
- 7The company repurchased 1 million shares of common stock for $29.8 million during 2002, as part of an ongoing share repurchase program.